ANI Pharmaceuticals (FRA:BSFA) Accumulated other comprehensive income (loss) : €3.3 Mil (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. ANI Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €3.3 Mil.

ANI Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 (€4.8 Mil) to Dec. 2024 (€5.1 Mil) but then declined from Dec. 2024 (€5.1 Mil) to Mar. 2025 (€3.3 Mil).

ANI Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2022 (€11.5 Mil) to Dec. 2023 (€8.1 Mil) and declined from Dec. 2023 (€8.1 Mil) to Dec. 2024 (€5.1 Mil).

ANI Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for ANI Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Accumulated other comprehensive income (loss) Chart

ANI Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-9.40

-2.70

11.49

8.12

5.10

ANI Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															8.65	7.74	4.84	5.10	3.34

ANI Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

ANI Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

ANIP:USA BSFA:Germany

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines